Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage 
Bayer’s Stroke Drug Achieves Breakthrough Trial Results, Boosting Market Confidence 
Federal Appeals Court Allows Trump’s National Guard Deployment in Washington, D.C. to Continue 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
Eli Lilly’s Weight-Loss Pill Nears Fast-Track FDA Approval as Profits Surge on Global Demand 
Pfizer Secures $10 Billion Deal for Obesity Drug Developer Metsera, Outbids Novo Nordisk 
New Epstein Photos Surface Showing Trump as Lawmakers Near Document Release Deadline 
Pfizer Boosts Bid for Metsera Amid Intensifying Rivalry with Novo Nordisk in Obesity Drug Market 
International Outcry Grows Over Re-Arrest of Nobel Laureate Narges Mohammadi in Iran 
Pfizer Sues Novo Nordisk Over Alleged Tactics to Block Obesity Drug Competition 
Novo Nordisk and Eli Lilly Lower Prices for Weight-Loss Drugs Amid U.S. Agreement 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
U.S. Reveals 2026 Medicare Star Ratings: Aetna, UnitedHealth Lead in Quality Scores 
Federal Judge Declines to Immediately Halt Trump’s $300 Million White House Ballroom Project 
On Monday, a U.S. appeals court ruled in favor of 3M, E.I. du Pont de Nemours and Co, and other manufacturers of "forever chemicals." The court rejected a lower court's ruling, allowing approximately 11.8 million Ohio residents to sue the companies.
Reuters noted that the ruling relieves considerable legal pressure placed on the chemical manufacturers to settle the plaintiffs' claims.
Court Ruling Questions Class Action Suit's Validity
According to Yahoo, Lead plaintiff Kevin Hardwick's complaint against the manufacturers faced scrutiny from the court. The appeals court found his complaint to be overly broad and lacking evidence that the per- and polyfluoroalkyl substances (PFAS) detected in his body could be directly attributed to the defendants.
The court emphasized that the complaint targeted the collective actions of the companies rather than individual responsibility. Notably, the case involved just 10 out of thousands of companies involved in PFAS manufacturing.
The lower court's approval of the class action suit has been vacated, and the court instructed the dismissal of Hardwick's lawsuit. The lawsuit aimed to hold the companies accountable for the health impacts of PFAS exposure and sought to establish a fund to monitor Ohio residents.
Additionally, Hardwick's request for the companies to fund studies on the health effects of PFAS was denied. These forever chemicals, commonly found in consumer products, have been linked to cancer and other diseases.
Robert Bilott, attorney for Hardwick, expressed disappointment with the court's decision. He stated that it contradicts what is known about the history of PFAS manufacturing in the United States. Bilott's legal team is currently evaluating whether to appeal the ruling further.
The Persistence and Prevalence of Forever Chemicals
PFAS substances earned the nickname "forever chemicals" due to their resistance to breaking down in nature or in the human body. The growing number of lawsuits filed against 3M, DuPont, and other manufacturers in recent years reflect concerns over alleged PFAS contamination.
In June, 3M agreed to pay $10.3 billion to settle hundreds of claims regarding public drinking water pollution caused by PFAS. Furthermore, Chemours Co, DuPont de Nemours Inc, and Corteva reached a similar settlement worth $1.19 billion with U.S. water providers.
Photo: 3M News Center
